Umbelliferone
Based on 5 publication(s) in Google Scholar
Umbelliferone (7-Hydroxycoumarin), a natural orally active product of the coumarin family, is a fluorescing compound which can be used as a sunscreen agent. Umbelliferone induces cell cycle arrest, apoptosis and DNA fragmentation in HepG2 cells. Umbelliferone exhibits significant anticancer effects. Umbelliferone attenuates the alteration characteristics of allergic airway inflammation. Umbelliferone displays the neuroprotective effects and cross the blood-brain barrier. Umbelliferone exhibits anti-inflammatory and antioxidant effects in chronic alcohol-fed rats.
For research use only. We do not sell to patients.
- Purity: 99.67%
- CAS No.: 93-35-6
- Formula: C9H6O3
- Molecular Weight:162.14
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Umbelliferone
More-
RT-PCR
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Bio/Physico-chemical Assay
-
RT-PCR
Biological Activity
|
Human Endogenous Metabolite |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>100 μM
Compound: 6
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 21696954] |
| A549 | IC50 |
21.11 μM
Compound: 7-C
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 28720504] |
| BT-549 | IC50 |
1 mM
Compound: 5
|
Antiproliferative activity against human BT549 cells after 24 hrs by MTT assay
Antiproliferative activity against human BT549 cells after 24 hrs by MTT assay
|
[PMID: 29144746] |
| HCT-116 | IC50 |
8.05 μM
Compound: 7
|
Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay
|
[PMID: 23746477] |
| HEK-293T | IC50 |
189.63 μM
Compound: 7-C
|
Antiproliferative activity against human 293T cells after 48 hrs by MTT assay
Antiproliferative activity against human 293T cells after 48 hrs by MTT assay
|
[PMID: 28720504] |
| HeLa | IC50 |
42.35 μM
Compound: 7-C
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 28720504] |
| HT-29 | IC50 |
22.67 μM
Compound: 7-C
|
Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 28720504] |
| HT-29 | IC50 |
4.35 μM
Compound: 7
|
Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay
|
[PMID: 23746477] |
| HUVEC | ED50 |
>5 μg/mL
Compound: 7-hydroxycoumarin
|
Cytotoxicity against HUVEC
Cytotoxicity against HUVEC
|
[PMID: 15043409] |
| KB | IC50 |
200 μM
Compound: 11.1
|
Antiproliferative activity against human KB cells measured after 48 hrs by MTT assay
Antiproliferative activity against human KB cells measured after 48 hrs by MTT assay
|
[PMID: 38340509] |
| LNCaP | ED50 |
>5 μg/mL
Compound: 7-hydroxycoumarin
|
Cytotoxicity against human LNCAP cells
Cytotoxicity against human LNCAP cells
|
[PMID: 15043409] |
| LNCaP | IC50 |
>20 μg/mL
Compound: 1
|
Inhibitory activity against 5-alpha-reductase type 1 in cell culture system using LNCaP cells (androgen-sensitive human prostatic cancer cell line)
Inhibitory activity against 5-alpha-reductase type 1 in cell culture system using LNCaP cells (androgen-sensitive human prostatic cancer cell line)
|
[PMID: 11527731] |
| LoVo | IC50 |
97 μM
Compound: 6
|
Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
Cytotoxicity against human LoVo cells after 72 hrs by MTT assay
|
[PMID: 21696954] |
| Lu1 | ED50 |
>5 μg/mL
Compound: 7-hydroxycoumarin
|
Cytotoxicity against human Lu1 cells
Cytotoxicity against human Lu1 cells
|
[PMID: 15043409] |
| MCF7 | ED50 |
>5 μg/mL
Compound: 7-hydroxycoumarin
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 15043409] |
| MCF7 | IC50 |
2.9 μM
Compound: 5
|
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
|
[PMID: 29144746] |
| MDA-MB-231 | IC50 |
3.7 μM
Compound: 5
|
Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
|
[PMID: 29144746] |
| MT4 | IC50 |
2341 μM
Compound: 7
|
Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
Cytotoxicity against human MT4 cells after 96 hrs by MTT assay
|
[PMID: 23746477] |
| P388 | ED50 |
0.4 μg/mL
Compound: umbelliferone, NSC-019790
|
Cytotoxicity against mouse P388 cells
Cytotoxicity against mouse P388 cells
|
[PMID: 6875580] |
| P388 | ED50 |
3.1 μg/mL
Compound: Umbelliferone
|
Cytotoxicity against mouse P388 cells
Cytotoxicity against mouse P388 cells
|
[PMID: 3783168] |
| PC-3 | IC50 |
>100 μM
Compound: 6
|
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 21696954] |
| SK-MEL-28 | IC50 |
>100 μM
Compound: 6
|
Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay
Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay
|
[PMID: 21696954] |
| SK-MEL-28 | IC50 |
0.48 μM
Compound: 5
|
Anticancer activity against human SK-MEL-28 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Anticancer activity against human SK-MEL-28 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 37197457] |
| SK-MEL3 | IC50 |
1.6 μM
Compound: 5
|
Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 24 hrs in presence of Artesunic acid by MTT assay
Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 24 hrs in presence of Artesunic acid by MTT assay
|
[PMID: 37197457] |
| SK-MEL3 | IC50 |
2.1 μM
Compound: 5
|
Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
Anticancer activity against human SK-MEL3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay
|
[PMID: 37197457] |
| SMMC-7721 | IC50 |
19.9 μM
Compound: 7-C
|
Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay
|
[PMID: 28720504] |
| U-373MG ATCC | IC50 |
>100 μM
Compound: 6
|
Cytotoxicity against human U373 cells after 72 hrs by MTT assay
Cytotoxicity against human U373 cells after 72 hrs by MTT assay
|
[PMID: 21696954] |
| V79 | IC50 |
58 μM
Compound: 7-Hydroxy-coumarin
|
Cytotoxicity against V-79 cells
Cytotoxicity against V-79 cells
|
10.1016/0960-894X(96)00315-0 |
Umbelliferone (1-50 μM, 12-48 h) induces a dose‑dependent and time‑dependent reduction in HepG2 cells viability[1].
Umbelliferone (0-50 μM, 24 h) results in the appearance of HepG2 cell shrinkage, membrane blebbing, nuclear condensation and apoptotic body formation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HepG2 cells
-
Concentration:0, 5, 25 50 μM
-
Incubation Time:24 h
-
Result:Resulted in the appearance of cell shrinkage and membrane blebbing, when compared with the morphology of untreated cells.
At 50 μM almost all the HepG2 cancer cells shrank significantly and no cells with normal morphological features were detected.
Reduced large nuclei.
Induced nuclear condensation and apoptotic body formation.
-
Cell Line:HepG2 cells
-
Concentration:0, 5, 25 50 μM
-
Incubation Time:24 h
-
Result:Increased in the proportion of cells in S phase (45.0, 51.3 and 62.1%, compared with 43.6% in untreated cells) and reduced in the fraction of cells in G1 phase (42.1, 45.6 and 32.2%, compared with 53.2% in the untreated cells).
Umbelliferone (15-30 mg/kg, i.g., daily, 21 days) shows neuroprotective effects on CUMS (chronic unpredictable mild stress)-induced rat model of depression, which is associated with the inhibition of neuronal apoptosis modulated by ROCK/Akt pathway[3].
Umbelliferone (0.05 g/L, p.o., daily, 8 weeks) protects against alcohol-induced liver damage by inhibiting the TLR4 signaling pathway and activating the antioxidant system in rats with liber-decarli liquid diet containing 5% alcohol [4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male BALB/c mice, 4-6 weeks old received systemic immunization by subcutaneous injection of 10 μg of chicken egg ovalbumin diluted in 2 mg/mL alum followed by a booster injection at day 14. A nasal challenge was performed starting at day 28, by inhalational exposure to aerosolised ovalbumin for 15 min/day, on five consecutive days[2].
-
Dosage:30, 60, 90 mg/kg
-
Administration:p.o., daily, 5 days
-
Result:Mice sensitized and challenged with ovalbumin have increased the number of inflammatory cells in bronchoalveolar lavage fluid.
Reduced the number of total cells and of neutrophils in the bronchoalveolar lavage fluid.
At 60 and 90 mg/kg, but not at 30 mg/kg, decreased significantly the number of eosinophils found in the bronchoalveolar lavage fluid of challenged mice.
At 60 mg/kg, decreased the number of mononuclear cells.
Caused a reduction in the levels of Th2-associated cytokines (IL-4, IL-5, IL-13).
-
Animal Model:While the control group of rats without receiving stress treatment had free access to food and water, other groups of rats were subjected to different types of stressors: cage tilting for 24 h, damp sawdust for 24 h, predator sounds, swimming in 4 ℃ cold water for 5min, swimming in 45 ℃ hot water for 5min, fasting for 48 h, water deprivation for 24 h, shaking for 15 min, nip trail for 1 min[3][5].
-
Dosage:15,30 mg/kg
-
Administration:i.g., daily, 21 days
-
Result:Exhibited an antidepressant-like effect, as sucrose consumption in CUMS rats significantly increased.
Decreased the expression of caspase3 and bax and increased the expression of bcl2 in CA1 region of hippocampus compared to the control group.
Remarkably increased the number of nissl-positive cells.
Down-regulated the levels of inflammatory cytokines IL-1β, IL-6 and TNF-α in hippocampus in the CUMS group versus control group.
Decreased the protein level of ROCK2 and phosphorylation expression of PTEN stimulated by CUMS.
Up-regulated the phosphorylation expressions of Akt and GSK3.
-
Animal Model:Rats were fed a Liber-Decarli liquid diet containing 5% alcohol for 8 weeks, while normal rats received an isocaloric carbohydrate liquid diet[4].
-
Dosage:0.05 g/L
-
Administration:p.o., daily, 8 weeks
-
Result:Decreased in serum TNF-α and IL-6 levels and increased IL-10 level.
Decreased the mRNA expressions of LBP, TLR4, NF-κB and TNF-α and IL-6.
Up-regulated SOD and CAT mRNA levels and activity.
Increased H2O2 and GSH levels and decreased hepatic MDA (Malondialdehyde) levels.
Chemical Information
-
CAS No. 93-35-6
-
Appearance Solid
-
Molecular Weight 162.14
-
Formula C9H6O3
-
SMILES
O=C1C=CC2=CC=C(O)C=C2O1
-
Synonyms
7-Hydroxycoumarin; Hydrangin; NSC 19790
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
J Agric Food Chem
Therapeutic Potential of Raspberry Extract in High-Fat Diet-Induced Liver Injury via Apoptosis and AMPK/PPARα Pathways. [Abstract]2025 Apr 1. PMID: 40168586 -
ACS Omega
2026 Mar 6;11(10):16756-16764. PMID: 41867607
Umbelliferone purchased from MedChemExpress. Usage Cited in: ACS Omega. 2026 Mar 6;11(10):16756-16764. [Abstract]
Cells were inoculated with culture medium alone (lanes 1, 5, and 9) or ZIKV (lanes 2–4), HCV (lanes 6–8), or JEV (lanes 10–12) and simultaneously treated with DMSO (vehicle, negative control), ribavirin (82 μM; positive control), or Umbelliferone (10 μM). Following the initial adsorption period (ZIKV, 6 h; HCV, 4 h; JEV, 1 h), the inoculum was replaced with fresh medium containing the same compounds. At 48 h postinfection (hpi), intracellular viral RNA was quantified via RT-qPCR using primers specific for viral NS1 and GAPDH.
Umbelliferone purchased from MedChemExpress. Usage Cited in: ACS Omega. 2026 Mar 6;11(10):16756-16764. [Abstract]
Dose-response analysis of ZIKV-infected cells treated with Umbelliferone (1, 5, 10, 20, 40, 80 μM). Data points represent mean ± SEM (n = 3). Significant inhibition was observed at concentrations ≥ 20 μM, yielding an estimated 50% inhibitory concentration (IC50) of 14.44 μM.
Umbelliferone purchased from MedChemExpress. Usage Cited in: ACS Omega. 2026 Mar 6;11(10):16756-16764. [Abstract]
Cytotoxicity of Umbelliferone in Vero E6 cells was assessed 48 h after treatment with DMSO or Umbelliferone (1–40 μM) using the CellTiter-Glo luminescent viability assay. Cell viability was calculated from relative luminescence units (RLU) and normalized to the DMSO group (100%).
Umbelliferone purchased from MedChemExpress. Usage Cited in: ACS Omega. 2026 Mar 6;11(10):16756-16764. [Abstract]
Evaluation of the anti-Zika efficacy of Umbelliferone derivatives. The four derivatives identified in Figure with no detectable cytotoxicity were selected to evaluate the antiviral activity against ZIKV in parallel with Umbelliferone. At 10 μM, a concentration at which Umbelliferone displayed robust antiviral activity, none of the derivatives exerted significant inhibitory effects.
Umbelliferone purchased from MedChemExpress. Usage Cited in: ACS Omega. 2026 Mar 6;11(10):16756-16764. [Abstract]
Vero E6 cells were infected with ZIKV at an MOI of 0.1 and treated with DMSO (negative control), ribavirin (82 μM; positive control), or Umbelliferone (10 μM). At 48 h postinfection (hpi), intracellular ZIKV RNA was quantified via RT-qPCR using primers specific for ZIKV NS1 and GAPDH.
-
J Biochem Mol Toxicol
The Protective Effects of Dose-Dependent Umbelliferone Application on CLP-Induced Acute Lung Injury (ALI) Model. [Abstract]2025 Oct;39(10):e70549. PMID: 41046538 -
J Pharm Biomed Anal
Determination of the in vitro metabolic stability and metabolites of the anticancer derivative riccardin D-N in human and mouse hepatic S9 fractions using HPLC-Q-LIT-MS. [Abstract]2019 Sep 10:174:734-743. PMID: 31299454 -
J Appl Toxicol
Umbelliferone protects against methylglyoxal-induced HUVECs dysfunction through suppression of apoptosis and oxidative stress. [Abstract]2023 Apr;43(4):490-499. PMID: 36170298
Solvent & Solubility
DMSO : 100 mg/mL (616.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1.43 mg/mL (8.82 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 1.43 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (14.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1.43 mg/mL (8.82 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 1.43 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (14.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Yu SM, et al. Umbelliferone exhibits anticancer activity via the induction of apoptosis and cell cycle arrest in HepG2 hepatocellular carcinoma cells. Mol Med Rep. 2015 Sep;12(3):3869-3873. [Content Brief]
[2]. Vasconcelos JF, et al. Effects of umbelliferone in a murine model of allergic airway inflammation. Eur J Pharmacol. 2009 May 1;609(1-3):126-31. [Content Brief]
[3]. Qin T, et al. Umbelliferone reverses depression-like behavior in chronic unpredictable mild stress-induced rats by attenuating neuronal apoptosis via regulating ROCK/Akt pathway. Behav Brain Res. 2017 Jan 15;317:147-156. [Content Brief]
[4]. Sim MO, et al. Anti-inflammatory and antioxidant effects of umbelliferone in chronic alcohol-fed rats. Nutr Res Pract. 2015 Aug;9(4):364-9. [Content Brief]
[5]. Luo DD, et al. Involvement of hippocampal serotonin and neuropeptide Y in depression induced by chronic unpredicted mild stress. Brain Res Bull. 2008 Sep 5;77(1):8-12. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 6.1675 mL | 30.8375 mL | 61.6751 mL | 154.1877 mL |
| 5 mM | 1.2335 mL | 6.1675 mL | 12.3350 mL | 30.8375 mL | |
| 10 mM | 0.6168 mL | 3.0838 mL | 6.1675 mL | 15.4188 mL | |
| 15 mM | 0.4112 mL | 2.0558 mL | 4.1117 mL | 10.2792 mL | |
| 20 mM | 0.3084 mL | 1.5419 mL | 3.0838 mL | 7.7094 mL | |
| 25 mM | 0.2467 mL | 1.2335 mL | 2.4670 mL | 6.1675 mL | |
| 30 mM | 0.2056 mL | 1.0279 mL | 2.0558 mL | 5.1396 mL | |
| 40 mM | 0.1542 mL | 0.7709 mL | 1.5419 mL | 3.8547 mL | |
| 50 mM | 0.1234 mL | 0.6168 mL | 1.2335 mL | 3.0838 mL | |
| 60 mM | 0.1028 mL | 0.5140 mL | 1.0279 mL | 2.5698 mL | |
| 80 mM | 0.0771 mL | 0.3855 mL | 0.7709 mL | 1.9273 mL | |
| 100 mM | 0.0617 mL | 0.3084 mL | 0.6168 mL | 1.5419 mL |